Erratum: Cardiorenal syndrome: the emerging role of protein-bound uremic toxins. (Circulation Research 2012;111:(1470-1483)). DOI: 10.1161/CIRCRESAHA.112.278457;Cardiorenal syndrome: The emerging role of protein-bound uremic toxins

Circulation Research

Volumn 111, Issue 11, 2012, Pages 1470-1483

  Lekawanvijit, Suree ^a,b   Kompa, Andrew R ^a,c   Wang, Bing H ^a   Kelly, Darren J ^c   Krum, Henry ^a  

^a MONASH UNIVERSITY   (Australia)

^b Faculty of Medicine Chiang Mai University   (Thailand)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

cardiorenal syndrome; heart failure; interstitial fibrosis; myocardial infarction; uremic cardiomyopathy

Indexed keywords

AST 120; INDICAN; UREMIC TOXIN;

ANEMIA; CARDIOMYOPATHY; CARDIORENAL SYNDROME; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DISEASE COURSE; FIBROGENESIS; HEART DISEASE; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY TRANSPLANTATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; RENAL REPLACEMENT THERAPY; REVIEW; URINARY EXCRETION;

EID: 84870024869     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/01.res.0000442686.77579.63     Document Type: Erratum

References (177)

1. Schrier RW. Cardiorenal versus renocardiac syndrome: is there a difference? Nat Clin Pract Nephrol. 2007;3:637.
2. Ronco C. Cardiorenal and renocardiac syndromes: clinical disorders in search of a systematic defnition. Int J Artif Organs. 2008;31:1-2.
3. Minino AM, Xu J, Kochanek KD, Tejada-Vera B. Death in the United States, 2007. NCHS Data Brief. 2009;26:1-8.
4. Kochanek KD, Xu J, Murphy SL, Minino AM, Kung HS. Deaths: preliminary Data for 2009. Nat Vital Stat Rep. 2011;4:59.
5. Berry C, Murdoch DR, McMurray JJ. Economics of chronic heart failure. Eur J Heart Fail. 2001;3:283-291.
6. Bundkirchen A, Schwinger RHG. Epidemiology and economic burden of chronic heart failure. Eur Heart J Suppl. 2004;6:D57-D60.
7. MacIntyre K, Capewell S, Stewart S, Chalmers JW, Boyd J, Finlayson A, Redpath A, Pell JP, McMurray JJ. Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation. 2000;102:1126-1131.
8. Shlipak MG. Pharmacotherapy for heart failure in patients with renal insuffciency. Ann Intern Med. 2003;138:917-924.
9. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insuffciency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35:681-689.
10. U.S. Renal Data System. USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007.
11. U.S. Renal Data System. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2010.
12. McCullough PA, Jurkovitz CT, Pergola PE, McGill JB, Brown WW, Collins AJ, Chen SC, Li S, Singh A, Norris KC, Klag MJ, Bakris GL; for the KEEP Investigators. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2007;167:1122-1129.
13. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insuffciency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134:629-636.
14. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285-1295.
15. Parikh CR, Coca SG, Wang Y, Masoudi FA, Krumholz HM. Long-term prognosis of acute kidney injury after acute myocardial infarction. Arch Intern Med. 2008;168:987-995.
16. Chae CU, Albert CM, Glynn RJ, Guralnik JM, Curhan GC. Mild renal insuffciency and risk of congestive heart failure in men and women > or =70 years of age. Am J Cardiol. 2003;92:682-686.
17. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305.
18. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffth JL, Salem DN, Levey AS, Sarnak MJ. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15:1307-1315.
19. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barré PE. The prognostic importance of left ventricular geometry in uremic cardiomy-opathy. J Am Soc Nephrol. 1995;5:2024-2031.
20. Raine AE, Margreiter R, Brunner FP, et al. Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant. 1992;7:7-35.
21. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154-2169.
22. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G. Defnition and classifcation of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089-2100.
23. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659-663.
24. Gross ML, Ritz E. Hypertrophy and fbrosis in the cardiomyopathy of uremia-beyond coronary heart disease. Semin Dial. 2008;21:308-318.
25. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;47:186-192.
26. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974;290:697-701.
27. U.S. Renal Data System. USRDS 1999 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; April 1999.
28. Wanner C, Krane V. Lessons learnt from the 4D trial. Nephrol Ther. 2006;2:3-7.
29. Amann K, Ritz E. Microvascular disease-the Cinderella of uraemic heart disease. Nephrol Dial Transplant. 2000;15:1493-1503.
30. Rostand SG, Kirk KA, Rutsky EA. Dialysis-associated ischemic heart disease: insights from coronary angiography. Kidney Int. 1984;25:653-659.
31. Glassock RJ, Pecoits-Filho R, Barberato SH. Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol. 2009;4 (Suppl 1):S79-S91.
32. Siedlecki AM, Jin X, Muslin AJ. Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure. Kidney Int. 2009;75:800-808.
33. Ritz E. Left ventricular hypertrophy in renal disease: beyond preload and afterload. Kidney Int. 2009;75:771-773.
34. Mall G, Rambausek M, Neumeister A, Kollmar S, Vetterlein F, Ritz E. Myocardial interstitial fbrosis in experimental uremia-implications for cardiac compliance. Kidney Int. 1988;33:804-811.
35. Amann K, Breitbach M, Ritz E, Mall G. Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol. 1998;9:1018-1022.
36. Macdougall IC, Lewis NP, Saunders MJ, Cochlin DL, Davies ME, Hutton RD, Fox KA, Coles GA, Williams JD. Long-term cardiorespira-tory effects of amelioration of renal anaemia by erythropoietin. Lancet. 1990;335:489-493.
37. Silverberg DS, Wexler D, Iaina A, Schwartz D. The correction of anemia in patients with the combination of chronic kidney disease and congestive heart failure may prevent progression of both conditions. Clin Exp Nephrol. 2009;13:101-106.
38. Jie KE, Verhaar MC, Cramer MJ, van der Putten K, Gaillard CA, Doevendans PA, Koomans HA, Joles JA, Braam B. Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors. Am J Physiol Renal Physiol. 2006;291:F932-F944.
39. Arcasoy MO. The non-haematopoietic biological effects of erythropoi-etin. Br J Haematol. 2008;141:14-31.
40. Attanasio P, Ronco C, Anker MS, Ponikowski P, Anker SD. Management of chronic cardiorenal syndrome. Contrib Nephrol. 2010;165:129-139.
41. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007;369:381-388.
42. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572-575.
43. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116:85-97.
44. Darley-Usmar V, Wiseman H, Halliwell B. Nitric oxide and oxygen radicals: a question of balance. FEBS Lett. 1995;369:131-135.
45. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141-1148.
46. Amann K, Törnig J, Buzello M, Kuhlmann A, Gross ML, Adamczak M, Buzello M, Ritz E. Effect of antioxidant therapy with dl-alpha-tocopher-ol on cardiovascular structure in experimental renal failure. Kidney Int. 2002;62:877-884.
47. Henry CB, Duling BR. TNF-alpha increases entry of macromolecules into luminal endothelial cell glycocalyx. Am J Physiol Heart Circ Physiol. 2000;279:H2815-H2823.
48. Steinberg D. A critical look at the evidence for the oxidation of LDL in atherogenesis. Atherosclerosis. 1997;131:S5-7.
49. Pober JS, Sessa WC. Evolving functions of endothelial cells in infam-mation. Nat Rev Immunol. 2007;7:803-815.
50. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med. 1998;339:1448-1456.
51. Yamaji T, Fukuhara T, Kinoshita M. Increased capillary permeability to albumin in diabetic rat myocardium. Circ Res. 1993;72:947-957.
52. Schwarz S, Trivedi BK, Kalantar-Zadeh K, Kovesdy CP. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol. 2006;1:825-831.
53. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12:2131-2138.
54. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol. 2005;16:1788-1793.
55. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcifcation and phosphate binder choice in incident hemo-dialysis patients. Kidney Int. 2007;71:438-441.
56. Amann K, Törnig J, Kugel B, Gross ML, Tyralla K, El-Shakmak A, Szabo A, Ritz E. Hyperphosphatemia aggravates cardiac fbrosis and microvas-cular disease in experimental uremia. Kidney Int. 2003;63:1296-1301.
57. Sangiorgi G, Rumberger JA, Severson A, Edwards WD, Gregoire J, Fitzpatrick LA, Schwartz RS. Arterial calcifcation and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology. J Am Coll Cardiol. 1998;31:126-133.
58. Keelan PC, Bielak LF, Ashai K, Jamjoum LS, Denktas AE, Rumberger JA, Sheedy II PF, Peyser PA, Schwartz RS. Long-term prognostic value of coronary calcifcation detected by electron-beam computed tomography in patients undergoing coronary angiography. Circulation. 2001;104:412-417.
59. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004;113:561-568.
60. Wolf M. Update on fbroblast growth factor 23 in chronic kidney disease. Kidney Int. 2012;82:737-747.
61. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, Sirkis R, Naveh-Many T, Silver J. The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007;117:4003-4008.
62. Kuro-o M. Klotho in health and disease. Curr Opin Nephrol Hypertens. 2012;21:362-368.
63. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro OM, Kusek JW, Keane MG, Wolf M. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121:4393-4408.
64. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, et al European Uremic Toxin Work Group (EUTox). Review on ure-mic toxins: classifcation, concentration, and interindividual variability. Kidney Int. 2003;63:1934-1943.
65. Dhondt A, Vanholder R, Van Biesen W, Lameire N. The removal of ure-mic toxins. Kidney Int Suppl. 2000;76:S47-S59.
66. Keshaviah P. Adequacy of CAPD: a quantitative approach. Kidney Int Suppl. 1992;38:S160-S164.
67. Makita Z, Bucala R, Rayfeld EJ, Friedman EA, Kaufman AM, Korbet SM, Barth RH, Winston JA, Fuh H, Manogue KR. Reactive glycosyl-ation endproducts in diabetic uraemia and treatment of renal failure. Lancet. 1994;343:1519-1522.
68. Meert N, Eloot S, Waterloos MA, Van Landschoot M, Dhondt A, Glorieux G, Ledebo I, Vanholder R. Effective removal of protein-bound uraemic solutes by different convective strategies: a prospective trial. Nephrol Dial Transplant. 2009;24:562-570.
69. Fenton SS, Schaubel DE, Desmeules M, Morrison HI, Mao Y, Copleston P, Jeffery JR, Kjellstrand CM. Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates. Am J Kidney Dis. 1997;30:334-342.
70. Fehske KJ, Müller WE, Platt KL, Stillbauer AE. Inhibition of benzo-diazepine receptor binding by several tryptophan ad indole derivatives. Biochem Pharmacol. 1981;30:3016-3019.
71. Niwa T, Takeda N, Tatematsu A, Maeda K. Accumulation of indoxyl sulfate, an inhibitor of drug-binding, in uremic serum as demonstrated by internal-surface reversed-phase liquid chromatography. Clin Chem. 1988;34:2264-2267.
72. Sarnatskaya VV, Yushko LA, Sakhno LA, Nikolaev VG, Nikolaev AV, Grinenko DV, Mikhalovsky SV. New approaches to the removal of protein-bound toxins from blood plasma of uremic patients. Artif Cells Blood Substit Immobil Biotechnol. 2007;35:287-308.
73. Lesaffer G, De Smet R, Lameire N, Dhondt A, Duym P, Vanholder R. Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane. Nephrol Dial Transplant. 2000;15:50-57.
74. Niwa T, Aiuchi T, Nakaya K, Emoto Y, Miyazaki T, Maeda K. Inhibition of mitochondrial respiration by furancarboxylic acid accumulated in ure-mic serum in its albumin-bound and non-dialyzable form. Clin Nephrol. 1993;39:92-96.
75. Ward RA. Protein-leaking membranes for hemodialysis: a new class of membranes in search of an application? J Am Soc Nephrol. 2005;16:2421-2430.
76. Owen WF Jr, Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med. 1993;329:1001-1006.
77. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990;15:458-482.
78. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease. J Am Soc Nephrol. 1996;7:728-736.
79. Winchester JF, Ronco C. Sorbent augmented hemodialysis systems: are we there yet? J Am Soc Nephrol. 2010;21:209-211.
80. Dou L, Bertrand E, Cerini C, Faure V, Sampol J, Vanholder R, Berland Y, Brunet P. The uremic solutes p-cresol and indoxyl sulfate inhibit endo-thelial proliferation and wound repair. Kidney Int. 2004;65:442-451.
81. Dou L, Jourde-Chiche N, Faure V, Cerini C, Berland Y, Dignat-George F, Brunet P. The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J Thromb Haemost. 2007;5:1302-1308.
82. Yamamoto H, Tsuruoka S, Ioka T, Ando H, Ito C, Akimoto T, Fujimura A, Asano Y, Kusano E. Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney Int. 2006;69:1780-1785.
83. Taki K, Tsuruta Y, Niwa T. Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients. Am J Nephrol. 2007;27:30-35.
84. Dou L, Cerini C, Brunet P, Guilianelli C, Moal V, Grau G, De Smet R, Vanholder R, Sampol J, Berland Y. P-cresol, a uremic toxin, decreases endothelial cell response to infammatory cytokines. Kidney Int. 2002;62:1999-2009.
85. Cerini C, Dou L, Anfosso F, Sabatier F, Moal V, Glorieux G, De Smet R, Vanholder R, Dignat-George F, Sampol J, Berland Y, Brunet P. P-cresol, a uremic retention solute, alters the endothelial barrier function in vitro. Thromb Haemost. 2004;92:140-150.
86. Peng YS, Ding HC, Lin YT, Syu JP, Chen Y, Wang SM. Uremic toxin p-cresol induces disassembly of gap junctions of cardiomyocytes. Toxicology. 2012;302:11-17.
87. Lin CJ, Wu CJ, Pan CF, Chen YC, Sun FJ, Chen HH. Serum protein-bound uraemic toxins and clinical outcomes in haemodialysis patients. Nephrol Dial Transplant. 2010;25:3693-3700.
88. de Loor H, Bammens B, Evenepoel P, De Preter V, Verbeke K. Gas chro-matographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clin Chem. 2005;51:1535-1538.
89. Liabeuf S, Barreto DV, Barreto FC, Meert N, Glorieux G, Schepers E, Temmar M, Choukroun G, Vanholder R, Massy ZA; European Uraemic Toxin Work Group (EUTox). Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant. 2010;25:1183-1191.
90. Meijers BK, Van Kerckhoven S, Verbeke K, Dehaen W, Vanrenterghem Y, Hoylaerts MF, Evenepoel P. The uremic retention solute p-cresyl sulfate and markers of endothelial damage. Am J Kidney Dis. 2009;54:891-901.
91. Neirynck N, Vanholder R, Schepers E, Eloot S, Pletinck A, Glorieux G. An update on uremic toxins. Int Urol Nephrol. August 15, 2012. doi:10.1007/s11255- 012-0258-1.
92. Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobsen DW, Robinson K, Dennis VW. Prospective study of hyperhomocystein-emia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation. 1998;97:138-141.
93. Thambyrajah J, Townend JN. Homocysteine and atherothrombosis-mechanisms for injury. Eur Heart J. 2000;21:967-974.
94. Hofmann MA, Lalla E, Lu Y, Gleason MR, Wolf BM, Tanji N, Ferran LJ Jr, Kohl B, Rao V, Kisiel W, Stern DM, Schmidt AM. Hyperhomocysteinemia enhances vascular infammation and accelerates atherosclerosis in a murine model. J Clin Invest. 2001;107:675-683.
95. Brown JC, Rosenquist TH, Monaghan DT. ERK2 activation by ho-mocysteine in vascular smooth muscle cells. Biochem Biophys Res Commun. 1998;251:669-676.
96. Van Campenhout A, Moran CS, Parr A, Clancy P, Rush C, Jakubowski H, Golledge J. Role of homocysteine in aortic calcifcation and osteo-genic cell differentiation. Atherosclerosis. 2009;202:557-566.
97. Qin X, Huo Y, Langman CB, Hou F, Chen Y, Matossian D, Xu X, Wang X. Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol. 2011;6:482-488.
98. Mann JF, Sheridan P, McQueen MJ, Held C, Arnold JM, Fodor G, Yusuf S, Lonn EM; HOPE-2 investigators. Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease-results of the renal Hope-2 study. Nephrol Dial Transplant. 2008;23:645-653.
99. Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM; Veterans Affairs Site Investigators. Effect of homocys-teine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA. 2007;298:1163-1170.
100. House AA, Eliasziw M, Cattran DC, Churchill DN, Oliver MJ, Fine A, Dresser GK, Spence JD. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA. 2010;303:1603-1609.
101. Spence JD, Stampfer MJ. Understanding the complexity of homocys-teine lowering with vitamins: the potential role of subgroup analyses. JAMA. 2011;306:2610-2611.
102. Lee JC, Downing SE. Negative inotropic effects of phenol on isolated cardiac muscle. Am J Pathol. 1981;102:367-372.
103. Iyngkaran P, Tuck KL, Ma J, Ho P, Lekawanvijit S, Kompa A, Wang B, Krum H. Do all protein bound renal toxins exert physiological effects on cardiac cells? Heart Lung Circ. 2009;18:S250-S251.
104. U.S. Renal Data System. USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2011.
105. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B, Cataliotti A, Malatino LS. Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int. 2004;65:1492-1498.
106. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol. 2001;12:2759-2767.
107. Covic A, Goldsmith DJ, Georgescu G, Venning MC, Ackrill P. Echocardiographic fndings in long-term, long-hour hemodialysis patients. Clin Nephrol. 1996;45:104-110.
108. Parfrey PS, Harnett JD, Foley RN, Kent GM, Murray DC, Barre PE, Guttmann RD. Impact of renal transplantation on uremic cardiomyopa-thy. Transplantation. 1995;60:908-914.
109. Okouchi Y, Arisaka H, Shimada A, Miyamoto K, Takase S, Suzuki T. Improvement of left ventricular function after renal transplantation in a patient with uremic cardiomyopathy: report of a case. Surg Today. 1993;23:998-1002.
110. Wali RK, Wang GS, Gottlieb SS, Bellumkonda L, Hansalia R, Ramos E, Drachenberg C, Papadimitriou J, Brisco MA, Blahut S, Fink JC, Fisher ML, Bartlett ST, Weir MR. Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. J Am Coll Cardiol. 2005;45:1051-1060.
111. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005;45:S1-153.
112. Stenvinkel P. New insights on infammation in chronic kidney disease-genetic and non-genetic factors. Nephrol Ther. 2006;2:111-119.
113. Goicoechea M, Quiroga B, García de Vinuesa S, Verdalles U, Reque J, Panizo N, Arroyo D, Santos A, Macías N, Luño J. Intraindividual in-terleukin-6 variations on the cardiovascular prognosis of patients with chronic renal disease. Ren Fail. 2012;34:1002-1009.
114. Meléndez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL. Interleukin 6 mediates myocardial fbrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension. 2010;56:225-231.
115. Zolty R, Hynes PJ, Vittorio TJ. Severe left ventricular systolic dysfunction may reverse with renal transplantation: uremic cardiomyopathy and cardiorenal syndrome. Am J Transplant. 2008;8:2219-2224.
116. Niwa T, Ise M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med. 1994;124:96-104.
117. Lim CF, Bernard BF, de Jong M, Docter R, Krenning EP, Hennemann G. A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia. J Clin Endocrinol Metab. 1993;76:318-324.
118. Enomoto A, Takeda M, Tojo A, Sekine T, Cha SH, Khamdang S, Takayama F, Aoyama I, Nakamura S, Endou H, Niwa T. Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J Am Soc Nephrol. 2002;13:1711-1720.
119. Kirkland JL, Vargas E, Lye M. Indican excretion in the elderly. Postgrad Med J. 1983;59:717-719.
120. Enomoto A, Endou H. Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease. Clin Exp Nephrol. 2005;9:195-205.
121. Stanfel LA, Gulyassy PF, Jarrard EA. Determination of indoxyl sulfate in plasma of patients with renal failure by use of ion-pairing liquid chro-matography. Clin Chem. 1986;32:938-942.
122. Ikegaya K, Nokihara K, Yasuhara T. Characterization of sulfhydryl heterogeneity in human serum albumin and recombinant human serum albumin for clinical use. Biosci Biotechnol Biochem. 2010;74:2232-2236.
123. Swan JS, Kragten EY, Veening H. Liquid-chromatographic study of fuo-rescent materials in uremic fuids. Clin Chem. 1983;29:1082-1084.
124. Meert N, Schepers E, De Smet R, Argiles A, Cohen G, Deppisch R, Drüeke T, Massy Z, Spasovski G, Stegmayr B, Zidek W, Jankowski J, Vanholder R. Inconsistency of reported uremic toxin concentrations. Artif Organs. 2007;31:600-611.
125. Nishio T, Takamura N, Nishii R, Tokunaga J, Yoshimoto M, Kawai K. Infuences of haemodialysis on the binding sites of human serum albumin: possibility of an effcacious administration plan using binding inhibition. Nephrol Dial Transplant. 2008;23:2304-2310.
126. Owada S, Goto S, Bannai K, Hayashi H, Nishijima F, Niwa T. Indoxyl sulfate reduces superoxide scavenging activity in the kidneys of normal and uremic rats. Am J Nephrol. 2008;28:446-454.
127. Atoh K, Itoh H, Haneda M. Serum indoxyl sulfate levels in patients with diabetic nephropathy: relation to renal function. Diabetes Res Clin Pract. 2009;83:220-226.
128. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classifcation, and stratifcation. Am J Kidney Dis. 2002;39:S1-266.
129. Shimizu H, Bolati D, Higashiyama Y, Nishijima F, Shimizu K, Niwa T. Indoxyl sulfate upregulates renal expression of MCP-1 via production of ROS and activation of NF-κB, p53, ERK, and JNK in proximal tubular cells. Life Sci. 2012;90:525-530.
130. Shimizu H, Bolati D, Adijiang A, Muteliefu G, Enomoto A, Nishijima F, Dateki M, Niwa T. NF-κB plays an important role in indoxyl sulfate-induced cellular senescence, fbrotic gene expression, and inhibition of proliferation in proximal tubular cells. Am J Physiol, Cell Physiol. 2011;301:C1201-C1212.
131. Shimizu H, Bolati D, Adijiang A, Enomoto A, Nishijima F, Dateki M, Niwa T. Senescence and dysfunction of proximal tubular cells are associated with activated p53 expression by indoxyl sulfate. Am J Physiol, Cell Physiol. 2010;299:C1110-C1117.
132. Eddy AA. Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions. J Am Soc Nephrol. 1994;5:1273-1287.
133. Miyazaki T, Ise M, Seo H, Niwa T. Indoxyl sulfate increases the gene expressions of TGF-beta 1, TIMP-1 and pro-alpha 1(I) collagen in uremic rat kidneys. Kidney Int Suppl. 1997;62:S15-S22.
134. Miyazaki T, Aoyama I, Ise M, Seo H, Niwa T. An oral sorbent reduces overload of indoxyl sulphate and gene expression of TGF-beta1 in urae-mic rat kidneys. Nephrol Dial Transplant. 2000;15:1773-1781.
135. Niwa T, Ise M, Miyazaki T. Progression of glomerular sclerosis in experimental uremic rats by administration of indole, a precursor of indoxyl sulfate. Am J Nephrol. 1994;14:207-212.
136. Tamada S, Asai T, Kuwabara N, Iwai T, Uchida J, Teramoto K, Kaneda N, Yukimura T, Komiya T, Nakatani T, Miura K. Molecular mechanisms and therapeutic strategies of chronic renal injury: the role of nuclear factor kappaB activation in the development of renal fbrosis. J Pharmacol Sci. 2006;100:17-21.
137. Sun CY, Hsu HH, Wu MS. p-Cresol sulfate and indoxyl sulfate induce similar cellular infammatory gene expressions in cultured proximal renal tubular cells. Nephrol Dial Transplant. May 18, 2012. doi:10.1093/ndt/gfs133. http://ndt.oxfordjournals.org/content/early/2012/05/17/ndt. gfs133.long. Accessed October 26, 2012.
138. Nistala R, Whaley-Connell A, Sowers Jr. Redox control of renal function and hypertension. Antioxid Redox Signal. 2008;10:2047-2089.
139. Tumur Z, Niwa T. Oral sorbent AST-120 increases renal NO synthesis in uremic rats. J Ren Nutr. 2008;18:60-64.
140. Gelasco AK, Raymond Jr. Indoxyl sulfate induces complex re-dox alterations in mesangial cells. Am J Physiol Renal Physiol. 2006;290:F1551- F1558.
141. Motojima M, Hosokawa A, Yamato H, Muraki T, Yoshioka T. Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells. Kidney Int. 2003;63:1671-1680.
142. Muteliefu G, Enomoto A, Jiang P, Takahashi M, Niwa T. Indoxyl sulphate induces oxidative stress and the expression of osteoblast-specifc proteins in vascular smooth muscle cells. Nephrol Dial Transplant. 2009;24:2051-2058.
143. Lekawanvijit S, Adrahtas A, Kelly DJ, Kompa AR, Wang BH, Krum H. Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac f-broblasts and myocytes? Eur Heart J. 2010;31:1771-1779.
144. Mann DL. Infammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 2002;91:988-998.
145. Muslin AJ. MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin Sci. 2008;115:203-218.
146. Liu S, Wang BH, Kompa AR, Lekawanvijit S, Krum H. Antagonists of organic anion transporters 1 and 3 ameliorate adverse cardiac remodelling induced by uremic toxin indoxyl sulfate. Int J Cardiol. 2012;158:457-458.
147. Lekawanvijit S, Kompa AR, Manabe M, Wang BH, Langham RG, Nishijima F, Kelly DJ, Krum H. Chronic kidney disease-induced cardiac fbrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate. PLoS ONE. 2012;7:e41281.
148. Fujii H, Nishijima F, Goto S, Sugano M, Yamato H, Kitazawa R, Kitazawa S, Fukagawa M. Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress. Nephrol Dial Transplant. 2009;24:2089-2095.
149. Takayama F, Taki K, Niwa T. Bifdobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemo-dialysis. Am J Kidney Dis. 2003;41:S142-S145.
150. Aoyama I, Niwa T. An oral adsorbent ameliorates renal overload of indoxyl sulfate and progression of renal failure in diabetic rats. Am J Kidney Dis. 2001;37:S7-S12.
151. Aoyama I, Shimokata K, Niwa T. An oral adsorbent downregulates renal expression of genes that promote interstitial infammation and fbrosis in diabetic rats. Nephron. 2002;92:635-651.
152. Nakagawa N, Hasebe N, Sumitomo K, Fujino T, Fukuzawa J, Hirayama T, Kikuchi K. An oral adsorbent, AST-120, suppresses oxidative stress in uremic rats. Am J Nephrol. 2006;26:455-461.
153. Sato T, Liang K, Vaziri ND. Protein restriction and AST-120 improve li-poprotein lipase and VLDL receptor in focal glomerulosclerosis. Kidney Int. 2003;64:1780-1786.
154. Akizawa T, Asano Y, Morita S, Wakita T, Onishi Y, Fukuhara S, Gejyo F, Matsuo S, Yorioka N, Kurokawa K; CAP-KD Study Group. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am J Kidney Dis. 2009;54:459-467.
155. Niwa T, Nomura T, Sugiyama S, Miyazaki T, Tsukushi S, Tsutsui S. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int Suppl. 1997;62:S23-S28.
156. Ueda H, Shibahara N, Takagi S, Inoue T, Katsuoka Y. AST-120 treatment in pre-dialysis period affects the prognosis in patients on hemodialysis. Ren Fail. 2008;30:856-860.
157. Mitsubishi Tanabe Pharma Corporation. A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1). ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US). 2000. http://clinicaltrials.gov/show/NCT00500682 NLM Identifer: NCT00500682. Accessed August 27, 2012.
158. Mitsubishi Tanabe Pharma Corporation. Kremezin Study Against Renal Disease Progression in Korea (K-STAR). ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US). 2000. http://clinicaltrials.gov/show/
159. Shibahara H, Shibahara N. Cardiorenal protective effect of the oral ure-mic toxin absorbent AST-120 in chronic heart disease patients with moderate CKD. J Nephrol. 2010;23:535-540.
160. Lekawanvijit S, Kompa AR, Manabe M, Kelly DJ, Krum H. Reduction of renal fbrosis as well as cardiac pro-fbrotic and pro-infammatory mRNA expression by an oral charcoal adsorbent, AST-120, in post-MI rats. Circulation. 2011;124:A11416.
161. Sun Y, Zhang J, Zhang JQ, Ramires FJ. Local angiotensin II and transforming growth factor-beta1 in renal fbrosis of rats. Hypertension. 2000;35:1078-1084.
162. Weber KT, Anversa P, Armstrong PW, Brilla CG, Burnett JC Jr, Cruickshank JM, Devereux RB, Giles TD, Korsgaard N, Leier CV. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol. 1992;20:3-16.
163. Epstein M. Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift. J Hypertens. 2001;19:829-842.
164. Widyantoro B, Emoto N, Nakayama K, Anggrahini DW, Adiarto S, Iwasa N, Yagi K, Miyagawa K, Rikitake Y, Suzuki T, Kisanuki YY, Yanagisawa M, Hirata K. Endothelial cell-derived endothelin-1 promotes cardiac fbrosis in diabetic hearts through stimulation of endothe-lial-to-mesenchymal transition. Circulation. 2010;121:2407-2418.
165. Hocher B, Thöne-Reineke C, Rohmeiss P, Schmager F, Slowinski T, Burst V, Siegmund F, Quertermous T, Bauer C, Neumayer HH, Schleuning WD, Theuring F. Endothelin-1 transgenic mice develop glo-merulosclerosis, interstitial fbrosis, and renal cysts but not hypertension. J Clin Invest. 1997;99:1380-1389.
166. Laredo J, Shah JR, Lu ZR, Hamilton BP, Hamlyn JM. Angiotensin II stimulates secretion of endogenous ouabain from bovine adre-nocortical cells via angiotensin type 2 receptors. Hypertension. 1997;29:401-407.
167. Komiyama Y, Dong XH, Nishimura N, Masaki H, Yoshika M, Masuda M, Takahashi H. A novel endogenous digitalis, telocinobufagin, exhibits elevated plasma levels in patients with terminal renal failure. Clin Biochem. 2005;38:36-45.
168. Elkareh J, Kennedy DJ, Yashaswi B, et al. Marinobufagenin stimulates fbroblast collagen production and causes fbrosis in experimental ure-mic cardiomyopathy. Hypertension. 2007;49:215-224.
169. Kennedy DJ, Vetteth S, Periyasamy SM, Kanj M, Fedorova L, Khouri S, Kahaleh MB, Xie Z, Malhotra D, Kolodkin NI, Lakatta EG, Fedorova OV, Bagrov AY, Shapiro JI. Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy. Hypertension. 2006;47:488-495.
170. Sun CY, Chang SC, Wu MS. Uremic toxins induce kidney fbrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition. PLoS ONE. 2012;7:e34026.
171. Schroeder JC, Dinatale BC, Murray IA, Flaveny CA, Liu Q, Laurenzana EM, Lin JM, Strom SC, Omiecinski CJ, Amin S, Perdew GH. The ure-mic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor. Biochemistry. 2010;49:393-400.
172. Carney SA, Chen J, Burns CG, Xiong KM, Peterson RE, Heideman W. Aryl hydrocarbon receptor activation produces heart-specifc transcriptional and toxic responses in developing zebrafsh. Mol Pharmacol. 2006;70:549-561.
173. Sanders JM, Bucher JR, Peckham JC, Kissling GE, Hejtmancik MR, Chhabra RS. Carcinogenesis studies of cresols in rats and mice. Toxicology. 2009;257:33-39.
174. Wu ZF, Liu GL, Zhou Z, Wang GX, Xia L, Liu JL. Induction of immune-related gene expression in Ctenopharyngodon idella kidney cells by secondary metabolites from immunostimulatory Alcaligenes faecalis FY-3. Scand J Immunol. 2012;76:131-140.
175. Satoh M, Hayashi H, Watanabe M, Ueda K, Yamato H, Yoshioka T, Motojima M. Uremic toxins overload accelerates renal damage in a rat model of chronic renal failure. Nephron Exp Nephrol. 2003;95:e111-e118.
176. McGregor D. Hydroquinone: an evaluation of the human risks from its carcinogenic and mutagenic properties. Crit Rev Toxicol. 2007;37:887-914.
177. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52:1527-1539.